In Brief: Columbia/HCA
Columbia/HCA: Amends merger agreement with Value Health so that each outstanding share of Value Health common stock will be exchanged for $20.50 in cash. Under the previous agreement, each share was to be exchanged for .58 shares of Columbia stock, which had an April 14 closing value of $18.20 per share. The merger is expected to be completed in the second quarter of 1997. Value Health also said it has received a letter from MedPartners proposing a merger in which each outstanding share of Value Health stock would be exchanged for 1.1 shares of MedPartners stock...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth